The estimated Net Worth of Bittoo Kanwar is at least $36.9 millier dollars as of 1 March 2023. Bittoo Kanwar owns over 539 units of Applied Molecular Transport stock worth over $20,281 and over the last 4 years Bittoo sold AMTI stock worth over $16,650.
Bittoo has made over 7 trades of the Applied Molecular Transport stock since 2021, according to the Form 4 filled with the SEC. Most recently Bittoo sold 539 units of AMTI stock worth $270 on 1 March 2023.
The largest trade Bittoo's ever made was exercising 31,500 units of Applied Molecular Transport stock on 22 December 2021 worth over $74,970. On average, Bittoo trades about 5,002 units every 63 days since 2020. As of 1 March 2023 Bittoo still owns at least 78,005 units of Applied Molecular Transport stock.
You can see the complete history of Bittoo Kanwar stock trades at the bottom of the page.
Bittoo's mailing address filed with the SEC is C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Applied Molecular Transport have traded over $9,673,149 worth of Applied Molecular Transport stock and bought 3,091,278 units worth $40,384,206 . The most active insiders traders include Capital Group, Llcepq Llc A..., Helen Susan Kim et Tahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of $26,155. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth $45,811.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Applied Molecular Transport executives and other stock owners filed with the SEC include: